Compound 35d is a promising novel anti-enteroviral candidate targeting viral transcription and translation for coxsackievirus infections.
MATERIALS & METHODS: Fifty-one novel 12N-substituted matrinic acid derivatives were synthesized and evaluated for their anti-coxsackievirus B3 activities. RESULTS: Structure-activity relationship studies revealed that the 11-side chain could be determinant for the selectivity index by adjusting overall lipophilicity, and 11-butane was the best one for both potency and druggability. The optimized 35d showed the broad-spectrum anti-coxsackieviruse effects, an excellent pharmacokinetics and a good safety profile. More importantly, it displayed a potential effect for the pleconaril-resistant coxsackievirus B3 as well. Its mode of action is targeting on the viral transcription and translation stage, a different mechanism from that of pleconaril. CONCLUSION: Thus, we considered that 35d is a promising anti-enteroviral candidate for the treatment of various diseases infected with coxsackieviruses.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2016) studied Coxsackievirus infection. 12N-substituted matrinic acid derivatives (compound 35d) vs. Pleconaril was evaluated on Anti-coxsackievirus B3 activities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: